伊贝沙坦对糖尿病大鼠肾小球毛细血管基底膜改变的影响-东南大学学报医学版

伊贝沙坦对糖尿病大鼠肾小球毛细血管基底膜改变的影响

单位：1.东南大学附属中大医院,江苏南京,210009； 2.东南大学基础医学院,江苏南京,210009

分类号：R962, R587.2, R965

出版年·卷·期（页码）：2002·21·第一期（89-92）

摘要：

目的:探讨血管紧张素Ⅱ受体拮抗剂伊贝沙坦(Irb)对链脲佐菌素(STZ)诱导的糖尿病大鼠肾小球毛细血管基底膜(GBM)改变的影响.方法:将SD大鼠随机分成正常对照(N)组、糖尿病肾病(DN)组和DN加Irb治疗(DNI)组3组.大鼠单侧肾切除后,腹腔注射STZ诱导糖尿病模型,观察治疗后第4、8、12周的血糖、体重、尿白蛋白排泄、肌酐清除率变化,同时观察12周时肾重、肾脏肥大指数、肾组织总蛋白含量、GBM厚度的改变.结果:DN组尿白蛋白排泄量较N组明显增加(P<0.01),肾重、肾脏肥大指数、肾组织总蛋白含量均较N组显著增加(P<0.05或<0.01).DNI组较DN组尿白蛋白排泄量减少(P<0.01),肌酐清除率水平下降(P<0.01),肾重、肾脏肥大指数、肾组织总蛋白含量均减少(P<0.01),糖尿病组GBM较正常对照组明显增厚(P<0.01),Irb可显著抑制GBM的增厚(P<0.01).结论:早期应用Irb对糖尿病大鼠有肾保护作用,并可能与抑制GBM增厚有关.

Objective To investigate the influence of angiotensin Ⅱ receptor antagonist irbesartan (Irb) on the glomerular basement membrane (GBM) in streptozotocin(STZ) induced diabetic rats.Methods SD rats were randomly divided into three groups:normal control rats (group N), diabetic rats (group DN) and diabetic rats treated with irbesartan (group DNI).Diabetes was induced by injection of STZ intraperitoneally after rats had received uninephrectomy.Blood glucose,body weight, urinary albumin excretion (Ualb),creatinine clearance (Ccr) were observed in the rats in 4,8,12 weeks after the treatment respectively.The kidney weight,profile of kidney hypertrophy,renal tissue protein contents,width of GBM were determined in 12 weeks, when the rats were sacrificed.Results Urinary albumin excretion in DN group was significantly increased compared with that in N group( P <0.01).Kidney weight,profile of kidney hypertrophy,renal tissue protein contents were markedly increased in DN group compared with that in N group( P <0.05, P <0.01,respectively).Ualb and Ccr were lower after diabetic rats received Irb( P <0.01).There was a reduction in kidney weight,profile of kidney hypertrophy,renal tissue protein contents in group DNI as compared to that in DN group ( P <0.01 respectively).GBM in DN group was thicker than that in N group ( P < 0.01 ),and Irb significantly restrained the thickening of GBM ( P <0.01).Conclusion Irb exerted renal protective effect on diabetic rats and inhibited the thickening of GBM.

参考文献：

[1] ZIYADEH F N. The extracellular matrix in diabetic nephropathy, 1993
[2] Leehey D J, SINGH A K, ALAVI N. Role of angiotensin Ⅱ in diabetic nephropathy. 2000(58). doi:10.1046/j.1523-1755.2000.07715.x
[3] Cao Z, BONNET F, DAVIS B. Additive hypotensive and anti-albuminuric effects of angiotensin-coverting enzyme inhibition and angiotensin receptor antagonist in diabetic spontaneously hypertensive rats. 2001. doi:10.1042/CS20000290
[4] Parving H H, LEHNERT H, BROCHNER-MORTENSEN J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. 2001. doi:10.1056/NEJMoa011489
[5] Kagami S, BORDER W A, MILLER D E. Angiotensin Ⅱ stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. 1994. doi:10.1172/JCI117251
[6] Toto R. Angiotensin Ⅱ subtype Ⅰ receptor blockers and renal function, 2001
[7] RUILOPE L M. Renoprotection and renin-angiotensin system blockade in diabetes mellitus. 1997. doi:10.1016/S0895-7061(97)00390-7
[8] O'Donnell M P, CRARY G S, da H. Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus, 1997(52)
[9] Lewis E J, HUNSICKER L G, BAIN RP. The effect of angiotensin-coverting enzyme inhibition on diabetic nephropathy. 1993. doi:10.1056/NEJM199311113292004
[10] Liu B C, SUN N, SUN Z L. Angiotensin Ⅱ receptor antagonist prevented the increasing of urinary excretion of TGF-β1 in patients with diabetic nephropathy, 2001
[11] Lewis E J, HUNSICKER L G, CLARKE W R. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. 2001. doi:10.1056/NEJMoa011303
[12] Park I S, KIYOMOTO H, ABBOUD S L. Expression of transforming growth factor-β and type Ⅳ collagen in early streptozotocin-induced diabetes. 1997. doi:10.2337/diabetes.46.3.473
[13] Werle E, HAO L, HASSLACHER C. Western blotting of NC1 type Ⅳ collagen fragments in human plasma. 1997(7). doi:10.1046/j.1365-2362.1997.1500701.x
[14] Mott J D, KHALIFAH R G, Nagase H. Nonenzymatic glycation of type Ⅳ collagen and matrix metalloproteinase susceptibility. 1997. doi:10.1038/ki.1997.455

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录